for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agios Pharmaceuticals Inc

AGIO.O

Latest Trade

55.79USD

Change

0.69(+1.25%)

Volume

529,317

Today's Range

55.21

 - 

56.65

52 Week Range

32.47

 - 

58.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
55.10
Open
55.56
Volume
529,317
3M AVG Volume
15.78
Today's High
56.65
Today's Low
55.21
52 Week High
58.93
52 Week Low
32.47
Shares Out (MIL)
69.94
Market Cap (MIL)
3,901.82
Forward P/E
2.21
Dividend (Yield %)
--

Next Event

Agios Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Agios Shareholders Approve Sale Of Oncology Business To Servier

Agios Submits Supplemental New Drug Application To FDA For Tibsovo (Ivosidenib Tablets) For Patients With Previously Treated Idh1-Mutant Cholangiocarcinoma

Agios Reports Fourth Quarter And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Industry

Business Services

Contact Info

88 Sidney St

CAMBRIDGE, MA

02139-4137

United States

+1.617.6498600

http://www.agios.com/

Executive Leadership

David P. Schenkein

Chairman of the Board

Jacqualyn A. Fouse

Chief Executive Officer, Director

Jonathan Prim Biller

Chief Financial Officer, Head of Legal and Corporate Affairs

Bruce Car

Chief Scientific Officer

Christopher J. Bowden

Chief Medical Officer

Key Stats

2.08 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.2K

2021(E)

0.0K
EPS (USD)

2018

-6.030

2019

-6.860

2020

-4.740

2021(E)

25.456
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.61
Price To Book (MRQ)
1.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
-24.22
Return on Equity (TTM)
-22.99

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up